NCT07684391Not yet recruiting
Effect of Oral Astaxanthin Formula on Pulmonary Rehabilitation in Patients With COPD
Effect of Oral Astaxanthin Formula Supplement on Pulmonary Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease: a Multicenter, Randomized Controlled Study
Source: ClinicalTrials.gov · Last updated 6 Jul 2026
Brief summary (registry, in English)
The goal of this clinical trial is to investigate whether an astaxanthin-based dietary supplement combined with a pulmonary rehabilitation training program could improve exercise capacity in patients with COPD. The main questions it aims to answer are: • whether an astaxanthin-based dietary supplement combined with a pulmonary rehabilitation training program could improve 6MWD in patients with COPD. The drug administration group will receive: * Two capsules of astaxanthin formula supplement daily for 8 weeks. * Pulmonary rehabilitation training: a total of 8 weeks, 2-3 times a week. The control group will receive a total of 8-week pulmonary rehabilitation training, 2-3 times a week. The investigators will compare the drug administration group and the control group to see if the difference between the 2 groups reaches a minimal clinically important difference.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- First submitted
- 13 Feb 2024
- Start date
- 1 Jul 2026
- Primary completion date
- 30 Sept 2026
- Lead sponsor
- China-Japan Friendship Hospital
- Diseases
- COPD
- NCT number
- NCT07684391
What you commit to
- Study type: Interventional
- Planned participants: 140
- From 1 Jul 2026 to the primary completion date, 30 Sept 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Hypoxemia (resting partial pressure of oxygen \< 60mmHg or oxygen saturation \< 88%) or patients requiring continuous oxygen therapy or with any contraindications to exercise testing (refer to the American Society of Thoracic Surgeons/American College of Chest Physicians exercise testing guidelines).
- Long-term oxygen therapy
Other illness
- History of other pulmonary diseases, including pneumoconiosis, bronchiectasis, tuberculosis, primary pulmonary hypertension, pulmonary embolism, interstitial lung disease
- Skeletal, neuromuscular, cardiovascular, or metabolic disorders that limit the participant's ability to exercise actively or that involve muscle activity, such as cancer, diabetes, muscle weakness, etc.
Other
- Using oral glucocorticoids
- Participated in a supervised exercise program within the past 12 months
Who the study is looking for
- Patients who met the GOLD diagnostic criteria for stage II-IV COPD
- Patients who met the indications for pulmonary rehabilitation training: mMRC score
- 3 or self-reported decline in physical function.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.